2024年7月3日 · Prolia (denosumab) is commonly used to treat osteoporosis, a condition in which the bones are thinner, weaker, and more prone to breakage. Prolia may be prescribed for …

2025年4月1日 · Prolia (denosumab) is an injection that is administered subcutaneously (under the skin) once every 6 months by a healthcare provider to treat osteoporosis in postmenopausal …

2024年5月2日 · Prolia (denosumab) is a monoclonal antibody used to treat bone loss (osteoporosis) in women who are at high risk for bone fracture after menopause. What Are …

Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors...

地诺单抗（denosumab,又称AMC-162，商品名Prolia）是一种有独特作用机制的骨吸收抑制剂，其特异性靶向核因子κB受体活化因子配体（receptor activator of NF-kB ligand, RANKL）,抑制 …

2024年3月25日 · Prolia is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic …

PROLIA (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for …

Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for …

Denosumab 60mg/mL; soln for SC inj; preservative-free. Osteoclast inhibitor (RANKL inhibitor). Binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and...

This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal …